Goldman Sachs Group Inc Intra Cellular Therapies, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 376,417 shares of ITCI stock, worth $48.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

376,417

Previous 456,030 17.46%

Holding current value

$48.1 Million

Previous $33.3 Million 5.72%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$71.19 - $91.57 $5.67 Million - $7.29 Million	-79,613 Reduced 17.46%	376,417 $31.4 Million
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $8.98 Million - $10.7 Million	-132,151 Reduced 22.47%	456,030 $33.3 Million
Q2 2024 Aug 13, 2024	SELL	$64.76 - $79.84 $11.5 Million - $14.2 Million	-178,246 Reduced 23.26%	588,181 $40.3 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $12.1 Million - $14.2 Million	187,812 Added 32.46%	766,427 $53 Million
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $9.25 Million - $14.7 Million	199,503 Added 52.62%	578,615 $41.4 Million
Q3 2023 May 14, 2024	SELL	$52.09 - $64.1 $10.4 Million - $12.8 Million	-199,503 Reduced 34.48%	379,112 $19.7 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $2.28 Million - $2.8 Million	43,690 Added 13.03%	379,112 $19.7 Million
Q2 2023 May 14, 2024	SELL	$54.67 - $66.44 $6.54 Million - $7.95 Million	-119,692 Reduced 26.3%	335,422 $21.2 Million
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $6.54 Million - $7.95 Million	-119,692 Reduced 26.3%	335,422 $21.2 Million
Q1 2023 May 14, 2024	BUY	$43.8 - $56.99 $4.41 Million - $5.74 Million	100,681 Added 28.41%	455,114 $24.6 Million
Q1 2023 May 11, 2023	BUY	$43.8 - $56.99 $4.41 Million - $5.74 Million	100,681 Added 28.41%	455,114 $24.6 Million
Q4 2022 May 14, 2024	SELL	$44.07 - $54.45 $12.9 Million - $15.9 Million	-292,813 Reduced 45.24%	354,433 $18.8 Million
Q4 2022 Feb 13, 2023	SELL	$44.07 - $54.45 $12.9 Million - $15.9 Million	-292,813 Reduced 45.24%	354,433 $18.8 Million
Q3 2022 May 14, 2024	BUY	$42.7 - $59.99 $766,550 - $1.08 Million	17,952 Added 2.85%	647,246 $30.1 Million
Q3 2022 Nov 10, 2022	BUY	$42.7 - $59.99 $766,550 - $1.08 Million	17,952 Added 2.85%	647,246 $30.1 Million
Q2 2022 May 14, 2024	BUY	$43.0 - $65.64 $2.18 Million - $3.33 Million	50,679 Added 8.76%	629,294 $35.9 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $6.47 Million - $9.88 Million	150,576 Added 31.45%	629,294 $35.9 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $9.43 Million - $15.1 Million	243,475 Added 103.5%	478,718 $29.3 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $12.4 Million - $18.8 Million	-351,743 Reduced 59.92%	235,243 $12.3 Million
Q3 2021 Nov 10, 2021	BUY	$28.72 - $42.49 $16.9 Million - $24.9 Million	586,986 New	586,986 $21.9 Million

Others Institutions Holding ITCI

# of Institutions

415

Shares Held

88.5M

Call Options Held

284K

Put Options Held

105K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Intra Cellular Therapies, Inc. Transaction History